Survey Discovers That Psilocybin Is Relatively Safe Drug

Findings from a large survey propose that psilocybin is a relatively safe drug, with less than 1% of users of psilocybin mushrooms seeking emergency medical care after consumption. The survey’s findings, which also propose that adverse incidents resulting in emergency medical care are often psychological in nature and can be resolved in 24 hours, were reported in the “Journal of Psychopharmacology.”

Psilocybin, which is the active ingredient found in hallucinogenic mushrooms, is known to induce a mind-altering state when consumed. While this compound is considered safe in comparison to other psychoactive substances, it can still cause adverse reactions such as panic attacks, paranoia and anxiety.

Thus far, numerous studies have found evidence suggesting that these mushrooms also hold properties that may be beneficial to mental health. King’s College London’s Emma Kopra, the author of the study, stated that the use of psychedelic substances by the general public had risen amid increasing public interest and research on their therapeutic potential.Kopra explained that it was important to gather more information on the drug’s safety profile, noting that despite prior evidence suggesting that psilocybin mushrooms were relatively safe, there existed scanty academic research on the nature and occurrence of adverse reactions.

Despite the drug’s positive press, researchers highlight that more studies are needed to guide public policy and the identification of safety precautions regarding psychedelic substances.

For their study, the researchers analyzed responses from the 2017 Global Drug Survey, with a focus on respondents who revealed that they had consumed psilocybin mushrooms. The researchers found that of the more than 9,000 respondents who reportedly consumed magic mushrooms, only 19 of them sought emergency medical treatment after ingesting the psychedelic.

The researchers also discovered that the most commonly cited symptoms by those who sought medical treatment were hearing/seeing things, suspiciousness/paranoia and panic/psychological anxiety. Other symptoms included difficulty breathing, passing out and seizures

The majority of the respondents who sought treatment also revealed that they had also consumed other substances, such as alcohol and cannabis, within the same time frame as the mushrooms. The researchers explain that mixing of substances or being in the wrong place or in the wrong mindset could have caused the adverse experiences to occur.

In the study’s report, Kopra noted that it was crucial that clear risk profiles and safety considerations be drawn for the recreational use of psilocybin mushrooms and the use of psilocybin in a research or clinical setting.

Other researchers involved in the study include James J. Rucker, Jason A. Ferris, Allan H. Young and Adam R. Winstock.

This research affirming the safety of psilocybin couldn’t have come at a better time given that plenty of companies, such as Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF), are engaged in developing novel medicines from various psychedelic compounds, not just psilocybin.

NOTE TO INVESTORS: The latest news and updates relating to Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) are available in the company’s newsroom at https://ibn.fm/DELCF

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Archives

Select A Month

PsychedelicNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050